Medical Information Only. Always consult your healthcare provider before enrolling in any clinical trial.
NCT00547508 · ClinicalTrials.gov registry record · Phase 3
To Determine How Different Doses of Tadalafil Work on Getting and Keeping an Erection 26 or 36 Hours After Taking
A Phase 3 study of Impotence, sponsored by Eli Lilly and Company.
- Completed
- Registry status
- Phase 3
- Development phase
- 485
- Enrollment target
- 1
- Study location
NCT00547508 is a Phase 3 study of Impotence that has completed, run by Eli Lilly and Company. The registered enrollment target is 485 participants. The trial reports 1 study location across 1 state.
The verdict
NCT00547508, a Phase 3 study of Impotence, has completed, sponsored by Eli Lilly and Company.
- COMPLETED
- Registry status
- Phase 3
- Development phase
- 485 participants
- Enrollment target
- 1
- Study location
Study Summary
Study to see how effective different doses of tadalafil are for getting and keeping an erection when sex is attempted after a certain number of hours.
Conditions Studied
Interventions
- DRUG placebo
- DRUG tadalafil
Study Locations (1)
Tennessee
- For additional information regarding investigative sites for this trial, contact 1-877-CTLILLY (1-877-285-4559, 1-317-615-4559) Mon - Fri from 9 AM to 5 PM Eastern Time (UTC/GMT - 5 hours, EST), or speak with your personal physician. - Knoxville
Trial Details
| Field | Value |
|---|---|
| Enrollment Target | 485 participants |
| Start Date | 2002-10 |
| Est. Completion | 2003-09 |
| Phase | Phase 3 |
Interested in This Trial?
Full Details on ClinicalTrials.gov ↗What the Registry Record Tells You About NCT00547508
The ClinicalTrials.gov registry entry for NCT00547508 describes a study currently listed as completed, categorized as Phase 3. The registered enrollment target is 485 participants, a figure that helps gauge the scale of data the investigators plan to collect. The listed sponsor is Eli Lilly and Company, which has 1,341 total studies on file at ClinicalTrials.gov.
The record links to 1 condition, with Impotence appearing as the primary indexed condition, and to 2 interventions - of which placebo is the first listed.
NCT00547508 reports 1 study location spanning 1 distinct geographic area - top geographies include Tennessee.
Frequently Asked Questions
What is clinical trial NCT00547508 about?
NCT00547508 is a clinical study titled "To Determine How Different Doses of Tadalafil Work on Getting and Keeping an Erection 26 or 36 Hours After Taking". Study to see how effective different doses of tadalafil are for getting and keeping an erection when sex is attempted after a certain number of hours.
What is the current status of trial NCT00547508?
This trial is currently completed. It is a Phase 3 study. The enrollment target is 485 participants. The study started on 2002-10. Estimated completion is 2003-09.
What conditions does trial NCT00547508 study?
This clinical trial studies the following conditions: Impotence.
What interventions are being tested in trial NCT00547508?
The interventions under investigation include: placebo (DRUG), tadalafil (DRUG).
Who is sponsoring clinical trial NCT00547508?
This trial is sponsored by Eli Lilly and Company, which has 1,341 total clinical trials registered on ClinicalTrials.gov.
Where is trial NCT00547508 being conducted?
This trial has 1 study location across Tennessee. Contact the study sites directly through ClinicalTrials.gov for enrollment availability.
Learn More About Clinical Trials
Read our methodology - how this data is sourced, computed, and verified.
Related
Every figure on PlainTrial is rendered directly from the ClinicalTrials.gov registry, no number is typed in by an editor. This page mirrors this trial's own ClinicalTrials.gov registry record, live from the dataset. See our editorial standards & corrections policy, the methodology behind these numbers, or report a data error.